RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy

Gan,Jing; Wang,Fangfang; Mu,Dezhi; Qu,Yi; Luo,Rong; Wang,Qiu

doi:10.3892/ol.2016.5261

RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy

Authors:
- Jing Gan
- Fangfang Wang
- Dezhi Mu
- Yi Qu
- Rong Luo
- Qiu Wang
View Affiliations

Affiliations: Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: October 14, 2016 https://doi.org/10.3892/ol.2016.5261
Pages: 4515-4523
Copyright: © Gan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinically, temozolomide (TMZ) is widely used in glioblastoma (GBM) treatment. However, the toxicity of TMZ may influence the quality of patient life. Thus, novel treatment options for sensitizing GBM cells to TMZ chemotherapy are necessary. Aurora‑A is widely expressed in GBM and correlated with poor prognosis. It has been proven to be an effective target for gene therapy and chemotherapy. In the present study, short hairpin (sh)RNA targeting Aurora‑A was employed to knockdown Aurora‑A expression in GBM cells. Cell Counting Kit‑8 assays, flow cytometry, colony formation assays, invasion assays and tube formation assays were used to determine the effects of Aurora‑A knockdown when combined with TMZ treatment. A U251 subcutaneous cancer model was established to evaluate the efficacy of combined therapy. The results of the present study indicated that the proliferation, colony formation, invasion and angiogenesis of GBM cells were significantly inhibited by combined therapy when compared with TMZ treatment alone. In vivo results demonstrated that knockdown of Aurora‑A significantly (P=0.0084) sensitizes GBM cells to TMZ chemotherapy. The results of the present study demonstrated that knockdown of Aurora‑A in GBM cells enhances TMZ sensitivity in vitro and in vivo. Therefore, Aurora‑A knockdown may be a novel treatment option for decreasing TMZ toxicity and improving patient quality of life.

View Figures

View References

1	Sathornsumetee S and Rich JN: New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther. 6:1087–1104. 2006. View Article : Google Scholar : PubMed/NCBI
2	Mrugala MM and Chamberlain MC: Mechanisms of disease: Temozolomide and glioblastoma-look to the future. Nat Clin Pract Oncol. 5:476–486. 2008. View Article : Google Scholar : PubMed/NCBI
3	Friedman HS, Kerby T and Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res. 6:2585–2597. 2000.PubMed/NCBI
4	Osoba D, Brada M, Yung WK and Prados M: Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol. 18:1481–1491. 2000.PubMed/NCBI
5	Margison GP, Santibáñez Koref MF and Povey AC: Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis. 17:483–487. 2002. View Article : Google Scholar : PubMed/NCBI
6	Hirose Y, Berger MS and Pieper RO: p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 61:1957–1963. 2001.PubMed/NCBI
7	Quiros S, Roos WP and Kaina B: Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle. 9:168–178. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ahluwalia MS, Xie H, Dahiya S, Hashemi-Sadraei N, Schiff D, Fisher PG, Chamberlain MC, Pannullo S, Newton HB, Brewer C, et al: Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: A phase II multicenter study. J Neurooncol. 122:111–119. 2015. View Article : Google Scholar : PubMed/NCBI
9	Taphoorn MJ, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason WP, Saran F, Nishikawa R, Hilton M, Theodore-Oklota C, et al: Health-Related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. J Clin Oncol. 33:2166–2175. 2015. View Article : Google Scholar : PubMed/NCBI
10	Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E and Saya H: Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem. 278:51786–51795. 2003. View Article : Google Scholar : PubMed/NCBI
11	Seki A, Coppinger JA, Jang CY, Yates JR and Fang G: Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science. 320:1655–1658. 2008. View Article : Google Scholar : PubMed/NCBI
12	Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR and Sen S: Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nature Genet. 20:189–193. 1998. View Article : Google Scholar : PubMed/NCBI
13	Sen S, Zhou H and White RA: A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene. 14:2195–2200. 1997. View Article : Google Scholar : PubMed/NCBI
14	Van Brocklyn JR, Wojton J, Meisen WH, Kellough DA, Ecsedy JA, Kaur B and Lehman NL: Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. Cancer Res. 74:5364–5370. 2014. View Article : Google Scholar : PubMed/NCBI
15	Yang H, Ou CC, Feldman RI, Nicosia SV, Kruk PA and Cheng JQ: Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res. 64:463–467. 2004. View Article : Google Scholar : PubMed/NCBI
16	Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA and Sen S: Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 36:55–62. 2004. View Article : Google Scholar : PubMed/NCBI
17	Qin L, Tong T, Song Y, Xue L, Fan F and Zhan Q: Aurora-A interacts with Cyclin B1 and enhances its stability. Cancer Lett. 275:77–85. 2009. View Article : Google Scholar : PubMed/NCBI
18	Sasayama T, Marumoto T, Kunitoku N, Zhang D, Tamaki N, Kohmura E, Saya H and Hirota T: Over-expression of Aurora-A targets cytoplasmic polyadenylation element binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1. Genes Cells. 10:627–638. 2005. View Article : Google Scholar : PubMed/NCBI
19	Yang S, He S, Zhou X, Liu M, Zhu H, Wang Y, Zhang W, Yan S, Quan L, Bai J and Xu N: Suppression of Aurora-A oncogenic potential by c-Myc downregulation. Exp Mol Med. 42:759–767. 2010. View Article : Google Scholar : PubMed/NCBI
20	Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, et al: Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol. 68:1291–1304. 2011. View Article : Google Scholar : PubMed/NCBI
21	Huck JJ, Zhang M, McDonald A, Bowman D, Hoar KM, Stringer B, Ecsedy J, Manfredi MG and Hyer ML: MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res. 8:373–384. 2010. View Article : Google Scholar : PubMed/NCBI
22	Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N, Marumoto T, Saya H and Horii A: RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 65:2899–2905. 2005. View Article : Google Scholar : PubMed/NCBI
23	Dai L, Cui X, Zhang X, Cheng L, Liu Y, Yang Y, Fan P, Wang Q, Lin Y, Zhang J, et al: SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin. Nat Commun. 7:19962016. View Article : Google Scholar
24	Dai L, Cheng L, Zhang X, Jiang Q, Zhang S, Wang S, Li Y, Chen X, Du T, Yang Y, et al: Plasmid-based STAT3-siRNA efficiently inhibits breast tumor growth and metastasis in mice. Neoplasma. 58:538–547. 2011. View Article : Google Scholar : PubMed/NCBI
25	Wang W, Dai LX, Zhang S, Yang Y, Yan N, Fan P, Dai L, Tian HW, Cheng L, Zhang XM, et al: Regulation of epidermal growth factor receptor signaling by plasmid-based microRNA-7 inhibits human malignant gliomas growth and metastasis in vivo. Neoplasma. 60:274–283. 2013. View Article : Google Scholar : PubMed/NCBI
26	Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP, Agrusa A, Dieli F, Zeuner A and Stassi G: Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res. 70:4655–4665. 2010. View Article : Google Scholar : PubMed/NCBI
27	Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP and Gilbert MR: Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 26:4189–4199. 2008. View Article : Google Scholar : PubMed/NCBI
28	Jiang Z, Pore N, Cerniglia GJ, Mick R, Georgescu MM, Bernhard EJ, Hahn SM, Gupta AK and Maity A: Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res. 67:4467–4473. 2007. View Article : Google Scholar : PubMed/NCBI
29	Woo SR, Ham Y, Kang W, Yang H, Kim S, Jin J, Joo KM and Nam DH: KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis. Biomed Res Int. 2014:7474152014. View Article : Google Scholar : PubMed/NCBI
30	Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, Mitchell L, Trivedi RN, Tang JB and Sobol RW: Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res. 71:2308–2317. 2011. View Article : Google Scholar : PubMed/NCBI
31	Park I, Mukherjee J, Ito M, Chaumeil MM, Jalbert LE, Gaensler K, Ronen SM, Nelson SJ and Pieper RO: Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. Cancer Res. 74:7115–7124. 2014. View Article : Google Scholar : PubMed/NCBI